Myricetin antagonizes semen-derived enhancer of viral infection (SEVI) formation and influences its infection-enhancing activity

Table 1 Combination index (CI) and dose-reduction values for inhibition of HIV-1_SF162 infection determined by combining myricetin with ARVs in semen^a

Drug combination, % inhibition	CI^b	Mean value for^a:
		Myr			ARVs
		Conc. (ng/ml)		Dose reduction	Conc. (ng/ml)		Dose reduction
Conc. (molar ratio)		Alone	Mixture	Dose reduction	Alone	Mixture	Dose reduction
Myr:AZT (1571:1)
50	0.331	600.52	105.97	5.67	0.37	0.06	6.17
90	0.145	16,962.76	1626.10	10.43	17.81	0.87	20.47
Myr:EFV (3142:1)
50	0.450	2040.81	654.58	3.12	0.80	0.10	8.00
90	0.466	9407.22	2299.93	4.09	1.64	0.36	4.56
Myr:MAR (2095:1)
50	0.275	1916.80	298.25	6.43	1.92	0.23	8.35
90	0.234	14,712.25	2335.84	6.30	24.03	1.80	13.35
Myr:RAL (3142:1)
50	0.413	1613.13	372.91	4.33	0.46	0.08	5.75
90	0.514	7554.10	2592.53	2.91	3.37	0.58	5.81
Myr:TNF (62.8:1)
50	0.051	1976.91	82.31	24.02	113.10	1.06	106.70
90	0.151	9440.37	1366.11	6.91	2721.14	17.57	154.87
Myr:NVP (628:1)
50	0.262	2199.95	183.01	12.02	2.15	0.38	5.66
90	0.437	15,403.41	1709.88	9.01	11.02	3.59	3.07

^aThe data shown are the means of three independent assays performed in triplicate
^bThe CI value reflects the nature of the interaction between compounds

ISSN: 1742-4690